JP7262100B2 - 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 - Google Patents

長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 Download PDF

Info

Publication number
JP7262100B2
JP7262100B2 JP2018556339A JP2018556339A JP7262100B2 JP 7262100 B2 JP7262100 B2 JP 7262100B2 JP 2018556339 A JP2018556339 A JP 2018556339A JP 2018556339 A JP2018556339 A JP 2018556339A JP 7262100 B2 JP7262100 B2 JP 7262100B2
Authority
JP
Japan
Prior art keywords
hdl
mtor
tissue
traf6i
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515926A (ja
JP2019515926A5 (enExample
Inventor
ムルダー，ウィレム
オチャンド，ジョーディ
ファヤド，ザヒ
ブラザ，ムーニア
デゥイベンブーアデン，ラファエル
フェイ，フランソワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2019515926A publication Critical patent/JP2019515926A/ja
Publication of JP2019515926A5 publication Critical patent/JP2019515926A5/ja
Priority to JP2023060872A priority Critical patent/JP2023085437A/ja
Application granted granted Critical
Publication of JP7262100B2 publication Critical patent/JP7262100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018556339A 2016-04-29 2017-05-01 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 Active JP7262100B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060872A JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329676P 2016-04-29 2016-04-29
US62/329,676 2016-04-29
PCT/US2017/030444 WO2017190145A1 (en) 2016-04-29 2017-05-01 Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060872A Division JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Publications (3)

Publication Number Publication Date
JP2019515926A JP2019515926A (ja) 2019-06-13
JP2019515926A5 JP2019515926A5 (enExample) 2020-06-18
JP7262100B2 true JP7262100B2 (ja) 2023-04-21

Family

ID=60161161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018556339A Active JP7262100B2 (ja) 2016-04-29 2017-05-01 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
JP2023060872A Pending JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060872A Pending JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Country Status (11)

Country Link
US (2) US20190290593A1 (enExample)
EP (2) EP3448364B1 (enExample)
JP (2) JP7262100B2 (enExample)
CN (2) CN116077439A (enExample)
AU (3) AU2017257189B2 (enExample)
CA (1) CA3021645A1 (enExample)
DK (1) DK3448364T3 (enExample)
ES (1) ES2913073T3 (enExample)
PL (1) PL3448364T3 (enExample)
PT (1) PT3448364T (enExample)
WO (1) WO2017190145A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085437A (ja) * 2016-04-29 2023-06-20 アイカーン スクール オブ メディスン アット マウント サイナイ 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018370237B2 (en) * 2017-11-20 2024-10-17 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
BR112022009934A2 (pt) * 2019-11-22 2022-08-09 Univ New York State Res Found Método para prevenir ou tratar diabetes tipo 1, e, composição compreendendo lipossomas
CN111494320A (zh) * 2020-04-24 2020-08-07 上海交通大学医学院附属仁济医院 一种载糖皮质激素的纳米载体及其制备和应用
CA3187283A1 (en) * 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022198101A1 (en) * 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
CN114788835B (zh) * 2022-04-07 2024-01-23 中山大学附属第三医院 Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252879A1 (en) 2010-10-26 2013-09-26 Industry-Academic Cooperation Foundation, Yeungnam University Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI66878C (fi) 1978-02-24 1984-12-10 Ciba Geigy Ag Foerfarande foer framstaellning av nya antigenderivat
JPS5528933A (en) 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
JPS5618996A (en) 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS58172399A (ja) 1982-04-05 1983-10-11 Dai Ichi Seiyaku Co Ltd ムラミルトリペプチド誘導体
EP0102319B1 (de) 1982-07-23 1987-08-19 Ciba-Geigy Ag Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen
ZA853989B (en) 1984-05-29 1986-01-29 Ciba Geigy Ag Acylated sugar derivatives,processes for their manufacture,and their use
JPS6157597A (ja) 1984-08-29 1986-03-24 Toshiyuki Hamaoka ムラミルペプチド活性エステル誘導体
EP0192609A3 (de) 1985-02-20 1988-04-27 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
EP0192611A3 (de) 1985-02-20 1988-05-11 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
US4640911A (en) 1985-05-29 1987-02-03 Ciba-Geigy Corporation Acylated sugar derivatives, processes for their manufacture, and their use
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE69230041T2 (de) 1991-11-19 2000-01-05 Peptech (Uk) Ltd., London Muramylverbindungen zur behandlung von septischem schock
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
GB9413935D0 (en) 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
GB9618673D0 (en) 1996-09-06 1996-10-16 Peptech Uk Ltd The use of muramyl peptides
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
KR20120105062A (ko) 2003-12-19 2012-09-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법
CN1942476A (zh) 2004-04-14 2007-04-04 惠氏公司 纳巴霉素42－酯衍生物的区位特异合成
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
CA2587411A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2009504192A (ja) 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
WO2008124165A2 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101096386A (zh) 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
JP5824213B2 (ja) 2007-10-05 2015-11-25 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体およびそれに関連する方法
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2217221B1 (en) 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
WO2009073984A1 (en) 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
WO2010048452A2 (en) 2008-10-22 2010-04-29 Kathryn Jill Chavez Polycyclic compounds and methods related thereto
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012026712A2 (ko) 2010-08-23 2012-03-01 주식회사 강스템홀딩스 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
US20140086839A1 (en) 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
CN102178954B (zh) 2011-04-25 2014-05-28 中国药科大学 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013192310A1 (en) * 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
EP2703384A1 (en) 2012-08-27 2014-03-05 Ludwig-Maximilians-Universität München Inhibitors of CD40-TRAF6 interaction
CN103589699B (zh) 2013-11-05 2015-05-13 江南大学 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶
EP4461372A3 (en) 2013-11-05 2025-01-22 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
WO2016138286A1 (en) 2015-02-26 2016-09-01 Stc.Unm Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
US11642419B2 (en) 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
CA2979712C (en) 2015-03-25 2024-01-23 The Regents Of The University Of Michigan Nanoparticle compositions for delivery of biomacromolecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
CA2983033A1 (en) 2015-04-20 2016-10-27 Memorial Sloan Kettering Cancer Center Imaging of tumor-associated macrophages
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
CN106714836A (zh) 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
JP2018521068A (ja) 2015-07-15 2018-08-02 セレーター ファーマシューティカルズ インコーポレイテッド 改善されたナノ粒子送達系
WO2017024312A1 (en) 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
EP3389635A4 (en) * 2015-12-18 2019-08-07 Northwestern University STAIN OXIDE-RELATED NANOPARTICLES OF SIMILARITY WITH HIGH-DENSITY LIPOPROTEINS
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
EP3448364B1 (en) * 2016-04-29 2022-02-09 Icahn School of Medicine at Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
WO2018071549A1 (en) 2016-10-11 2018-04-19 New York University Nanoparticles and uses thereof
CN106831614B (zh) 2017-01-09 2020-07-28 清华大学 取代的苯并二氮杂环类化合物及其制备方法和用途
IL302880A (en) 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
AU2018370237B2 (en) 2017-11-20 2024-10-17 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
EP3713548A4 (en) 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
KR102198900B1 (ko) 2019-05-10 2021-01-07 서강대학교 산학협력단 질병 치료용 나노입자 복합체 및 이의 제조방법
WO2022198101A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
EP4499052A2 (en) 2022-03-31 2025-02-05 Icahn School of Medicine at Mount Sinai Sphingolipid-loaded nanobiologics for immune regulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252879A1 (en) 2010-10-26 2013-09-26 Industry-Academic Cooperation Foundation, Yeungnam University Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Intl. Soc. Mag. Reson. Med.，2014年，Vol. 22，p. 2821

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085437A (ja) * 2016-04-29 2023-06-20 アイカーン スクール オブ メディスン アット マウント サイナイ 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Also Published As

Publication number Publication date
AU2022204675B2 (en) 2025-09-04
AU2025217324A1 (en) 2025-09-04
PL3448364T3 (pl) 2022-08-16
CA3021645A1 (en) 2017-11-02
US20190290593A1 (en) 2019-09-26
JP2019515926A (ja) 2019-06-13
EP3448364B1 (en) 2022-02-09
EP4014967A1 (en) 2022-06-22
JP2023085437A (ja) 2023-06-20
AU2017257189A1 (en) 2018-11-15
US12377054B2 (en) 2025-08-05
CN109640959A (zh) 2019-04-16
CN109640959B (zh) 2023-03-17
AU2017257189B2 (en) 2022-03-31
WO2017190145A1 (en) 2017-11-02
PT3448364T (pt) 2022-05-04
EP3448364A1 (en) 2019-03-06
US20230218537A1 (en) 2023-07-13
ES2913073T3 (es) 2022-05-31
AU2022204675A1 (en) 2022-09-15
DK3448364T3 (da) 2022-05-02
EP3448364A4 (en) 2019-12-25
CN116077439A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
US12377054B2 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
KR102509006B1 (ko) 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체
US20180064662A1 (en) Novel compositions and uses of metformin agents
US20250213665A1 (en) Methods for inhibiting trained immunity with nanobiologic compositions
US8642033B2 (en) Methods for inducing in vivo tolerance
JP2020502094A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
WO2016180781A1 (en) Combination therapy of mesothelioma
EP3836951A1 (en) Peptides and compositions for targeted treatment and imaging
AU2024208037B2 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
JP6878418B2 (ja) 移植片拒絶反応の処置方法
CA3243686A1 (en) ORGANIC COMPOUNDS
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
EA043659B1 (ru) Иммуноаблативные виды терапии
HK40008076B (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230404

R150 Certificate of patent or registration of utility model

Ref document number: 7262100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150